Your browser doesn't support javascript.
loading
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors.
Meulendijks, Didier; Lassen, Ulrik N; Siu, Lillian L; Huitema, Alwin D R; Karanikas, Vaios; Mau-Sorensen, Morten; Jonker, Derek J; Hansen, Aaron R; Simcox, Mary E; Schostack, Kathleen J; Bottino, Dean; Zhong, Hua; Roessler, Markus; Vega-Harring, Suzana M; Jarutat, Tiantom; Geho, David; Wang, Karen; DeMario, Mark; Goss, Glenwood D; Schellens, Jan H M.
Afiliación
  • Meulendijks D; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Lassen UN; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
  • Siu LL; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Huitema AD; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Karanikas V; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Zurich, Switzerland.
  • Mau-Sorensen M; Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark.
  • Jonker DJ; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada.
  • Hansen AR; Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Simcox ME; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Schostack KJ; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Bottino D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Zhong H; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Roessler M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany.
  • Vega-Harring SM; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany.
  • Jarutat T; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, Penzberg, Germany.
  • Geho D; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Wang K; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • DeMario M; Roche Pharmaceutical Research and Early Development, Roche Innovation Center, New York, New York.
  • Goss GD; Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada.
  • Schellens JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. Department of Pharmaceutical Sciences, Science Faculty, Utrecht University, Utrecht, the Netherlands. j.schellens@nki.nl.
Clin Cancer Res ; 22(4): 858-67, 2016 Feb 15.
Article en En | MEDLINE | ID: mdl-26446946
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Receptores del Factor de Necrosis Tumoral / Anticuerpos Monoclonales / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Biomarcadores de Tumor / Receptores del Factor de Necrosis Tumoral / Anticuerpos Monoclonales / Antineoplásicos Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos